Cabazitaxel Versus the Switch to Alternative AR-targeted Agent (Enzalutamide or Abiraterone) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Patients Previously Treated With Docetaxel and Who Rapidly Failed a Prior AR-targeted Agent

Exclusion Criteria

• •Prior chemotherapy other than docetaxel for prostate cancer, except estramustine and except adjuvant/neoadjuvant treatment completed \>3 years ago.
• •Less than 28 days elapsed from prior treatment with chemotherapy, immunotherapy, radiotherapy, or surgery to the time of randomization.
• •Eastern Cooperative Oncology Group performance status (ECOG PS) \>2 (ECOG 2 must be related to prostate cancer, not to other comorbidities).
• •Prior malignancy. Adequately treated basal cell or squamous cell skin or superficial (pTis, pTa, and pT1) bladder cancer were allowed, as well as any other cancer for which treatment has been completed \>=5 years ago and from which the participant has been disease-free for \>=5 years.
• •Participation in another clinical trial and any concurrent treatment with any investigational drug within 30 days prior to randomization.
• •Acquired immunodeficiency syndrome (AIDS-related illnesses) or known human immunodeficiency virus (HIV) disease requiring antiretroviral treatment.
• •Participants with reproductive potential who do not agree, in conjunction with their partner, to use accepted and effective method of contraception during the study treatment period and up to 6 months after the last administered dose. The definition of "effective method of contraception" described hereafter: oral contraceptives, combined hormonal intravaginal, transdermal, intra uterine device or condoms was based on respective study treatment labelling and country-specific regulatory requirements, and were documented in the Informed Consent Form.
• •Known allergies, hypersensitivity or intolerance to prednisone or excipients of abiraterone acetate, enzalutamide, docetaxel, or polysorbate 80.
• •Known history of mineralocorticoid excess or deficiency.
• •History of seizure, underlying brain injury with loss of consciousness, transient ischemic attack within the past 12 months, cerebral vascular accident, brain arteriovenous malformation, brain metastases, or the use of concomitant medications that may lower the seizure threshold.
• •Unable to swallow a whole tablet or capsule.
• •Inadequate organ and bone marrow function as evidenced by:
• •Hemoglobin \<10.0 g/dL;
• •Absolute neutrophil count \<1.5 \* 10\^9/L;
• •Platelet count \<100 \* 10\^9/L;
• •Aspartate aminotransferase/serum glutamic oxaloacetic transaminase and/or alanine aminotransferase/serum glutamic pyruvic transaminase \>1.5 \* the upper limit of normal (ULN);
• •Total bilirubin \>1.0 \* ULN;
• •Potassium \<3.5 mmol/L;
• •Child-Pugh Class C.
• •Contraindications to the use of corticosteroid treatment.
• •Symptomatic peripheral neuropathy Grade \>=2 (NCI CTCAE v4.0).
• •Uncontrolled severe illness or medical condition including uncontrolled diabetes mellitus, history of cardiovascular disease (uncontrolled hypertension, arterial thrombotic events in the past 6 months, congestive heart failure, severe or unstable angina pectoris, recent myocardial infarction within the last 6 months, or uncontrolled cardiac arrhythmia).
• •Concomitant vaccination with yellow fever vaccine.
• •The above information was not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.